Similar articles

• Perforating dermatosis in a patient receiving bevacizumab.

  Vano-Galvan S, Moreno C, Medina J, Pérez-García B, García-López JL, Jaén P. Vano-Galvan S, et al. J Eur Acad Dermatol Venereol. 2009 Aug;23(8):972-4. doi: 10.1111/j.1468-3083.2008.03078.x. Epub 2009 Mar 17. J Eur Acad Dermatol Venereol. 2009. PMID: 19470057 No abstract available.
• First description of an uterine perforation potentially imputable to treatment with bevacizumab.

  Uguen T, Leconte B, Desgrippes R, Tchoundeu B, Bretagne JF, Manfredi S. Uguen T, et al. Acta Oncol. 2012 Nov;51(8):1102-4. doi: 10.3109/0284186X.2012.689855. Epub 2012 Oct 1. Acta Oncol. 2012. PMID: 23020310 No abstract available.
• [Bevacizumab in the treatment of colorectal carcinoma: news from ASCO 2008].

  Mansueto G, Longo F. Mansueto G, et al. Tumori. 2008 Jul-Aug;94(4):suppl 1-14. Tumori. 2008. PMID: 18822711 Review. Italian. No abstract available.
• Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.

  Duffy A, Shia J, Huitzil-Melendez FD, Fong Y, O'Reilly EM. Duffy A, et al. Clin Colorectal Cancer. 2008 Mar;7(2):140-3. doi: 10.3816/CCC.2008.n.019. Clin Colorectal Cancer. 2008. PMID: 18501074
• [The development of the first line treatment of metastatic colorectal cancer (mCRC)].

  Landherr L, Nagykálnai T. Landherr L, et al. Magy Onkol. 2009 Sep;53(3):237-46. doi: 10.1556/MOnkol.53.2009.3.1. Magy Onkol. 2009. PMID: 19793687 Review. Hungarian.